# US 2019/0375772 A1 · Pegylated imidazoquinolines as tlr7 and tlr8 agonists

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0375772 A1
- Document ID: US20190375772A1
- Status: Published application
- Kind: A1
- Application number: 16/459,776
- Filed: 2019-07-02
- Published: 2019-12-12
- Earliest claimed: 2015-12-14
- Assignees: Glaxosmithkline Biologicals SA
- Applicants: GlaxoSmithKline Biologicals SA
- Inventors: Helene G. BAZIN-LEE; David A. Johnson
- Web page: https://patentgrep.com/patent/US20190375772A1

## CPC

- C07F 9/6561: containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- A61P 17/12: Keratolytics, e.g. wart or anti-corn preparations
- A61P 31/14: for RNA viruses
- A61P 31/20: for DNA viruses
- A61P 35/00: Antineoplastic agents
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides novel phospholipidated imidazoquinolines as TLR7 and TLR8 agonists, pharmaceutical compositions, therapeutic uses and processes for preparing the same.

## Claims

### Claim 1

A compound, or a pharmaceutically acceptable salt thereof, of formula (I):
wherein
R1 is selected from H, C1-6alkyl, C1-6alkylamino, C1-6alkoxy, C3-6cycloalkylC1-6alkyl, C3-6cycloalkylC1-6alkylamino, C3-6cycloalkylC1-6alkoxy, C1-6alkoxyC1-6alkyl, C1-6alkoxyC1-6alkylamino and C1-6alkoxyC1-6alkoxy; wherein the C1-6alkyl, C1-6alkylamino, C1-6alkoxy, C3-6cycloalkylC1-6alkyl, C3-6cycloalkylC1-6alkylamino, C3-6cycloalkylC1-6alkoxy, C1-6alkoxyC1-6alkyl, C1-6alkoxyC1-6alkylamino or C1-6alkoxyC1-6alkoxy is branched or unbranched and optionally terminally substituted with a hydroxyl, amino, thio, hydrazino, hydrazido, azido, acetylenyl, carboxyl, or maleimido group;
Z is selected from C2-C6 alkyl and C2-C6 alkenyl, wherein the C2-C6 alkyl or C2-C6 alkenyl is unsubstituted or terminally substituted by —(O—C2-C6alkyl)1-6—;
X is O or S;
n is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20;
R2 is H or a straight or branched, optionally unsaturated, C4-C24 alkyl, or a straight or branched, optionally unsaturated, C4-C24, acyl;
R3 is a straight or branched, optionally unsaturated, C4-C24 alkyl or a straight or branched, optionally unsaturated, C4-C24 acyl.

### Claim 2 (depends on 1)

The compound or pharmaceutically acceptable salt according to claim 1 wherein R1 is selected from H, C1-6alkyl, C1-6alkylamino and C1-6alkoxy wherein the C1-6alkyl, C1-6alkylamino or C1-6alkoxy is branched or unbranched and optionally terminally substituted with a hydroxyl, amino, thio, hydrazino, hydrazido, azido, acetylenyl, carboxyl, or maleimido group.

### Claim 3 (depends on 1)

The compound or pharmaceutically acceptable salt according to claim 1 wherein R1 is n-butyl.

### Claim 4 (depends on 1)

The compound or pharmaceutically acceptable salt of claim 1 wherein Z is (CH2)2.

### Claim 5 (depends on 1)

The compound or pharmaceutically acceptable salt of claim 1 wherein X is O.

### Claim 6 (depends on 1)

The compound or pharmaceutically acceptable salt of claim 1 wherein n is selected from 3 or 6.

### Claim 7 (depends on 1)

The compound or pharmaceutically acceptable salt of claim 1 wherein R2 is a straight or branched, optionally unsaturated, C4-C24 acyl.

### Claim 8 (depends on 1)

The compound or pharmaceutically acceptable salt of claim 1 wherein R3 is a straight or branched, optionally unsaturated, C4-C24 acyl.

### Claim 9 (depends on 1)

The compound or pharmaceutically acceptable salt of claim 1 wherein R2 is unbranched C16 acyl (palmitoyl, COC15H31).

### Claim 10 (depends on 1)

The compound or pharmaceutically acceptable salt of claim 1 wherein R3 is unbranched C16 acyl (palmitoyl, COC15H31).

### Claim 11 (depends on 1)

The compound of claim 1 wherein R1=n-butyl; Z is (CH2)2; n is selected from 3, 6 and 9; R2 is unbranched C16 acyl (palmitoyl, COC15H31) and R3 is unbranched C16 acyl (palmitoyl, COC15H31).

### Claim 12

A compound selected from the group consisting of
4-amino-1-[2-(1,2-dipalmitoyl-sn-glycero-3-ethyleneglycol-phospho)ethyl]-2-n-butyl-1H-imidazo[4,5-c]quinoline;
4-amino-1-[2-(1,2-dipalmitoyl-sn-glycero-3-triethyleneglycol-phospho)ethyl]-2-n-butyl-1H-imidazo[4,5-c]quinoline;
4-amino-1-[2-(1,2-dipalmitoyl-sn-glycero-3-hexaethyleneglycol-phospho)ethyl]-2-n-butyl-1H-imidazo[4,5-c]quinoline;
4-amino-1-[2-(1,2-dipalmitoyl-sn-glycero-3-nonaethyleneglycol-phospho)ethyl]-2-n-butyl-1H-imidazo[4,5-c]quinoline;
and pharmaceutically acceptable salts thereof.

### Claim 13

4-amino-1-[2-(1,2-dipalmitoyl-sn-glycero-3-triethyleneglycol-phospho)ethyl]-2-n-butyl-1H-imidazo[4,5-c]quinoline:
or a pharmaceutically acceptable salt thereof.

### Claim 14

4-amino-1-[2-(1,2-dipalmitoyl-sn-glycero-3-hexaethyleneglycol-phospho)ethyl]-2-n-butyl-1H-imidazo[4,5-c]quinoline:
or a pharmaceutically acceptable salt thereof.

### Claim 15 (depends on 1)

A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier or diluent.

### Claim 16 (depends on 1)

A method for the treatment of hepatitis C viral infection in a mammal in need thereof comprising administering to said subject a therapeutically effective amount of a compound according to claim 1.

### Claim 17 (depends on 1)

A method for the treatment of basal cell carcinoma in a mammal in need thereof comprising administering to said subject a therapeutically effective amount of a compound according to claim 1.

### Claim 18 (depends on 1)

A method for the treatment of actinic keratosis in a mammal in need thereof comprising administering to said subject a therapeutically effective amount of a compound according to claim 1.

### Claim 19 (depends on 1)

A method for the treatment of genital papilloma viral infection in a mammal in need thereof comprising administering to said subject a therapeutically effective amount of a compound according to claim 1.

### Claim 20

(canceled)

### Claim 21

(canceled)

### Claim 22 (depends on 1)

A process for preparing a compound according to claim 1 comprising the steps of:
a) reacting a compound of formula (III)
wherein
n is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20;
R2 is H or a straight or branched, optionally unsaturated, C4-C24 alkyl, or a straight or branched, optionally unsaturated, C4-C24, acyl;
R3 is a straight or branched, optionally unsaturated, C4-C24 alkyl or a straight or branched, optionally unsaturated, C4-C24 acyl.
with a compound of formula (V)
wherein
PG is a protecting group suitable for hydroxyl protection, including but not limited to cyanoethyl, methyl, ethyl, benzyl and allyl group
to prepare a compound of formula (VI)
wherein
R is
b) reacting a compound of formula (VI) with a compound of formula (VII)
wherein
R1 is selected from H, C1-6alkyl, C1-6alkylamino, C1-6alkoxy, C3-6cycloalkylC1-6alkyl, C3-6cycloalkylC1-6alkylamino, C3-6cycloalkylC1-6alkoxy, C1-6alkoxyC1-6alkyl, C1-6alkoxyC1-6alkylamino and C1-6alkoxyC1-6alkoxy; wherein the C1-6alkyl, C1-6alkylamino, C1-6alkoxy, C3-6cycloalkylC1-6alkyl, C3-6cycloalkylC1-6alkylamino, C3-6cycloalkylC1-6alkoxy, C1-6alkoxyC1-6alkyl, C1-6alkoxyC1-6alkylamino or C1-6alkoxyC1-6alkoxy is branched or unbranched and optionally terminally substituted with a hydroxyl, amino, thio, hydrazino, hydrazido, azido, acetylenyl, carboxyl, or maleimido group;
Z is selected from C2-C6 alkyl and C2-C6 alkenyl, wherein the C2-C6 alkyl or C2-C6 alkenyl is unsubstituted or terminally substituted by —(O—C2-C6alkyl)1-6—;
to prepare a compound of formula (IX)
wherein
R is
R′ is
wherein PG is a protecting group suitable for hydroxyl protection, including but not limited to cyanoethyl, methyl, ethyl, benzyl and allyl group;
c) oxidizing a compound of formula (IX) and removing the hydroxyl protecting group to obtain a compound of formula (I)

### Claim at position 23

23-35. (canceled)
